search
Back to results

Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States

Primary Purpose

Hyper-IgM Syndrome, Ectodermal Dysplasia

Status
Terminated
Phase
Locations
United States
Study Type
Observational
Intervention
Sponsored by
National Institute of Allergy and Infectious Diseases (NIAID)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Hyper-IgM Syndrome focused on measuring CD40 Ligand, Nemo, Genetics, Hyper-IGM, Ectodermal Dysplasia, CVID, Hyper-IgM Syndrome, Primary Immune Deficiency Disorders, Common Variable Immune Deficiency

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

INCLUSION CRITERIA: All patients must have a known or suspected immune defect with hyper-IgM syndrome and/or disorders of immunoglobulin production. There will be no limit on age, sex, race, or disability. Normal volunteers must be healthy adults between the age of 18 and 70 years. All study participants enrolled on to this study must agree to allow PI to store research samples. Refusal to let PI store samples may lead to withdrawal fro this specific study. EXCLUSION CRITERIA: The presence of an acquired abnormality, which leads to immune defects, such as HIV, chemotherapy, and malignancy are general exclusion criteria. Refusal to let us store samples may lead to withdrawal from this specific study. Other factors, which are in the judgment of the Principal Investigator PI that may interfere with patient evaluation or determine to pose an added risk for study participants are also criteria for exclusion.

Sites / Locations

  • National Institutes of Health Clinical Center, 9000 Rockville Pike

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
December 16, 2005
Last Updated
October 5, 2017
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
search

1. Study Identification

Unique Protocol Identification Number
NCT00266513
Brief Title
Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States
Official Title
Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States
Study Type
Observational

2. Study Status

Record Verification Date
July 11, 2013
Overall Recruitment Status
Terminated
Study Start Date
December 14, 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 11, 2013 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)

4. Oversight

5. Study Description

Brief Summary
This study investigates gene abnormalities in Primary Immune Deficiency(PID) with a goal of improving the diagnosis and treatment of patients. The specific disorders include: X linked hyper IgM Syndrome which is caused by an abnormality in the CD40L gene. NEMO associated immune deficiency which is caused by an abnormality in a gene called NEMO. Common variable immunodeficiency (CVID) which has an unknown genetic basis. Other disorders of immunoglobulin production. This study will: Better characterize the clinical features of CD40 L deficiency and NEMO associated immune deficiency and other related primary immune deficiency syndromes. Determine the frequency of CD40 L and Nemo abnormalities. Determine whether particular abnormalities in these genes are associated with more of less severe illness or with specific symptoms. Explore the basic mechanism by which these altered genes cause immune dysfunction. Identify other genes causing low immune globulin levels and related primary immune deficient states.
Detailed Description
This protocol is designed to study the genetics and pathophysiology of Hyper-IgM syndrome, NEMO associated immune deficiency, patients with related primary immune deficiency disorders, and the blood relatives of immunodeficient patients. Patients will undergo evaluations that include history/physical, blood sampling, genetic testing, and possible tissue sampling. Among the aims of this protocol are to better understand genetic factors that lead to defects in host defense, and to use modern and evolving methods in molecular and cellular biology to elucidate the pathogenesis of these diseases. A better understanding of primary immunodeficiency could allow for the rational development of novel therapies for such diseases and to benefit future patients, but it might not benefit current patients directly. Routine follow-up may occur every six months - with evaluation and blood sampling. Under some circumstances, we may provide treatment that relates to the immune deficiency. These treatments will follow standard medical practice.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyper-IgM Syndrome, Ectodermal Dysplasia
Keywords
CD40 Ligand, Nemo, Genetics, Hyper-IGM, Ectodermal Dysplasia, CVID, Hyper-IgM Syndrome, Primary Immune Deficiency Disorders, Common Variable Immune Deficiency

7. Study Design

Enrollment
119 (Actual)

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
INCLUSION CRITERIA: All patients must have a known or suspected immune defect with hyper-IgM syndrome and/or disorders of immunoglobulin production. There will be no limit on age, sex, race, or disability. Normal volunteers must be healthy adults between the age of 18 and 70 years. All study participants enrolled on to this study must agree to allow PI to store research samples. Refusal to let PI store samples may lead to withdrawal fro this specific study. EXCLUSION CRITERIA: The presence of an acquired abnormality, which leads to immune defects, such as HIV, chemotherapy, and malignancy are general exclusion criteria. Refusal to let us store samples may lead to withdrawal from this specific study. Other factors, which are in the judgment of the Principal Investigator PI that may interfere with patient evaluation or determine to pose an added risk for study participants are also criteria for exclusion.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ashish K Jain, M.D.
Organizational Affiliation
National Institute of Allergy and Infectious Diseases (NIAID)
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institutes of Health Clinical Center, 9000 Rockville Pike
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
15661022
Citation
Durandy A, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev. 2005 Feb;203:67-79. doi: 10.1111/j.0105-2896.2005.00222.x.
Results Reference
background
PubMed Identifier
10207167
Citation
Jain A, Atkinson TP, Lipsky PE, Slater JE, Nelson DL, Strober W. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest. 1999 Apr;103(8):1151-8. doi: 10.1172/JCI5891.
Results Reference
background
PubMed Identifier
14975260
Citation
Durandy A, Revy P, Fischer A. Human models of inherited immunoglobulin class switch recombination and somatic hypermutation defects (hyper-IgM syndromes). Adv Immunol. 2004;82:295-330. doi: 10.1016/S0065-2776(04)82007-8. No abstract available.
Results Reference
background

Learn more about this trial

Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States

We'll reach out to this number within 24 hrs